COSCIENS Biopharma Inc. (CSCI)
CSCI Stock Price Chart
Explore COSCIENS Biopharma Inc. interactive price chart. Choose custom timeframes to analyze CSCI price movements and trends.
CSCI Company Profile
Discover essential business fundamentals and corporate details for COSCIENS Biopharma Inc. (CSCI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 1996
Employees
40.00
Website
https://www.cosciensbio.comCEO
Anna Elizabeth Biehn
Description
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
CSCI Financial Timeline
Browse a chronological timeline of COSCIENS Biopharma Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.85 , while revenue for the quarter reached $2.75M .
Earnings released on 9 Apr 2025
EPS came in at -$2.15 surpassing the estimated -$3.48 by +38.22%, while revenue for the quarter reached $1.50M , beating expectations by +35.95%.
Earnings released on 28 Mar 2025
EPS came in at -$4.64 , while revenue for the quarter reached $3.32M .
Earnings released on 12 Nov 2024
EPS came in at -$1.85 surpassing the estimated -$3.48 by +46.84%, while revenue for the quarter reached $1.90M , beating expectations by +72.73%.
Earnings released on 13 Aug 2024
EPS came in at -$0.64 surpassing the estimated -$3.28 by +80.49%, while revenue for the quarter reached $2.30M , beating expectations by +109.09%.
Earnings released on 14 May 2024
EPS came in at -$4.74 falling short of the estimated -$3.24 by -46.30%, while revenue for the quarter reached $4.00K , missing expectations by -99.64%.
Stock split effective on 3 May 2024
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Mar 2024
EPS came in at -$1.16 falling short of the estimated -$0.97 by -19.59%, while revenue for the quarter reached $100.00K .
Earnings released on 9 Nov 2023
EPS came in at -$3.40 falling short of the estimated -$2.44 by -39.34%.
Earnings released on 9 Aug 2023
EPS came in at -$2.08 surpassing the estimated -$3.48 by +40.23%, while revenue for the quarter reached $2.20M , beating expectations by +92.98%.
Earnings released on 9 May 2023
EPS came in at -$3.52 surpassing the estimated -$4.28 by +17.76%, while revenue for the quarter reached $2.10M , beating expectations by +133.33%.
Earnings released on 23 Mar 2023
EPS came in at -$10.24 falling short of the estimated -$3.72 by -175.27%, while revenue for the quarter reached $2.50M , beating expectations by +135.85%.
Earnings released on 3 Nov 2022
EPS came in at -$2.80 falling short of the estimated -$2.72 by -2.94%, while revenue for the quarter reached $1.86M , missing expectations by -53.50%.
Earnings released on 3 Aug 2022
EPS came in at -$3.48 falling short of the estimated -$2.72 by -27.94%, while revenue for the quarter reached -$222.00K , missing expectations by -116.95%.
Stock split effective on 21 Jul 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
CSCI Stock Performance
Access detailed CSCI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.